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Poster Session I 43expression and production of IL-15, IL-12 and IL-18 in activated
CB (Qian/Cairo, Blood, 1997; Lee/Cairo, Blood 1996; Satwani/
Cairo, Br J Haem, 2005) may contribute to diminished CB cellular
immunity and delayed immune reconstitution after UCBT.
NKCD3-/561 effector cells recognize target cells and express activat-
ing and inhibitory receptors. NKTCD31/561 cells may also play
a role in allograft and tumor cytotoxicity. We reported the ability
to EvE cryopreserved, thawed, recryopreserved, rethawed CB
with increased NKbright/dim subsets expressing KIRs and NCR
with enhanced in-vitro and in-vivo cytotoxicity (Ayello/Cairo.
BBMT, 2006). In this study, we compare 2 vs 7 d expansion and ac-
tivation of NK and NKT subsets expressing NKRs and the produc-
tion of IL-15, IL-18 and IFN-g. Rethawed CB cells were cultured
with anti-CD3, IL-2, IL-7 and IL-12; 2–7 days. CD3, CD16,
CD56, CD94, NKG2A, NKG2D, NKp46, KIR2DS4, KIR3DL1,
LAMP-1 and granzyme B expression were determined by flow cy-
tometry; IL-15, IL-18 and IFN-g protein by ELISA. Non-adherent
total cells were significantly increased (6.26 214  107 vs 5.86 57
 106, p\ 0.001) with no change in NKdim subset; but significant
increased NKT subset (71.8 6 6.0 vs 2.97 6 0.3%, p\ 0.001).
NKbright cells were decreased (3.3 6 1.1 vs 13.4 6 1.4%, p \
0.01); whereas, NKTbright subset was significantly increased (10.6
6 1.4 vs 0.7 6 0.1%, p \ 0.05). NK KIRdim/bright subsets were
not significantly increased, but NKT KIR3DL1dim subset was in-
creased (17.1 6 1.2 vs 1.1 6 0.5%, p\ 0.05). CD94/NKG2A ex-
pression was decreased (7.8 6 1.3 vs 22.7 6 1.0%, p \ 0.001.)
while CD94/NKG2D was increased (41.4 6 0.4 vs 23.7 6 2.0%,
p\ 0.001). NK and NKT KIR2DS4 subsets were increased (24.8
6 0.1 vs 3.1 6 0.4%, p\ 0.001; 19.0 6 0.6 vs 1.0 6 0.1%, p\
0.001, respectively), as well as CD107a (65.3 6 2.2 vs 12.95 6
1.5%, p\ 0.001), granzyme B (33.6 6 0.61 vs 25.8 6 1.79%, p\
0.01), and IL-18 and IFN-g protein production (730 6 4.7 vs 183
6 8.8 pg/ml, p\ 0.001; 37.3 6 7.6 vs 21 6 1.4 pg/ml, p\ 0.05).
In summary, CB MNC may be thawed at time of UCBT, recryopre-
served, rethawed, and activated for up to 7 d to yield increased NK
and NKT subsets with increased KAR expression (KIR2DS4,
CD94/NKG2D), NK activation (CD107a), and production of IL-
18 and IFN-g, suggesting that cryopreserved CB cells may be
EvE for potential use as ACI for DLI after UCBT.Results N 5 46 Values reported as Median (Range)
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LENALIDOMIDE DIRECTLY UPREGULATES NK (NATURAL KILLER) CELL
TRAIL AND GRANZYME B EXPRESSION: IMPLICATIONS FOR ADOPTIVE
NK CELL IMMUNOTHERAPY FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HCT)
Srivastava, S.1, Lundqvist, A.2, Berg, M.2, Yokoyama, H.2, Smith, A.2,
McCoy, J.P.2, Childs, R.2 1 Indiana University, Indianapolis, IN; 2Na-
tional Heart, Lung and Blood Institute, NIH, Bethesda, MD.
Immunomodulatory drugs have been shown to increase NK cell
numbers, and augment NK-cell dependent cytotoxicity in vivo.
Therefore, we investigated the effect of culturing fresh and ex-
panded NK cells in vitro with lenalidomide as a potential method
to augment their antitumor activity for subsequent adoptive infu-
sion following allogeneic HCT.
Methods: CD3-/CD561NK cells were isolated using immuno-
magnetic beads. Freshly isolated NK cells and in vitro expanded NK
cells (using irradiated EBV- LCL feeders and IL-2 over 10–14 days)
were treated with lenalidomide (0.4–40 mcg/ml) over 48–84 hours
in IL-2 (500 u/ml) containing media. The phenotype of lenalido-
mide treated NK cells and corresponding DMSO controls (vehicle
for lenalidomide) were characterized by flow-cytometry. The cyto-
toxicity of lenalidomide treated NK cells and corresponding
DMSO controls vs K562 cells and human renal cell carcinoma cells
was assessed by chromium release assay at varying effector to target
ratios (1.25:1 to 10:1). Results: Immunophenotypical analysis
showed in-vitro expanded NK cells treated with lenalidomide up-
regulated expression of granzyme-B; the MFI (mean fluorescence
intensity) in lenalidomide treated expanded NK cells compared to
untreated controls increased from 42726 3 to 51846 89. Similarly,
TRAIL surface expression increased in lenalidomide cultured NKcells; compared to controls, the MFI increased from 24.6 6 4.3 to
30.7 6 4.6 in lenalidomide treated expanded NK cells and 12.1 6
0.3 to 14.9 6 1.9 in lenalidomide treated fresh NK cells. Interest-
ingly, compared to controls, lenalidomide decreased NKG2D ex-
pression in expanded NK cells (MFI 128.6 6 31.6 to 70.7 6
22.8). Despite lenalidomide induced up-regulation of NK cell
TRAIL and granzyme B, cytotoxicity assays did not show significant
differences in killing of K562 cells or RCC lines by lenalidomide
treated vs untreated NK cells. Conclusion: Culturing fresh and ex-
panded NK cells in lenalidomide increased TRAIL and granzyme B
expression but did not enhance NK cell cytotoxicity of tumor tar-
gets. The decline in NKG2D expression in lenalidomide treated
cells may have offset any potential increase in NK cell cytotoxicity
expected to occur as a consequence of upregulating granzyme B
and TRAIL. Prior studies showing in vivo enhancement in NK
cell numbers and cytotoxicity after treatment with lenalidomide
may be related to the effects of this drug on other cellular popula-
tions which indirectly enhance NK cell function in vivo.112
PROCESSING CRYOPRESERVED LOW CELL DOSE UMBILICAL CORD
BLOOD FOR ADULT TRANSPLANTATION WITH MINIMAL MANIPULA-
TION AND CELL LOSS: A SINGLE INSTITUTION EXPERIENCE
Parthasarathy, M., Rodriguez, T., Smith, S., Lu, S., Stiff, P. Loyola
University Medical Center, Maywood, IL.
Hematopoietic Stem Cells from Umbilical Cord Blood (UCB)
are increasingly being used as an alternative to marrow or peripheral
blood stem cells in adults. Most Cord Blood Centers have recom-
mend a post thaw washing step to remove the cryoprotectant
DMSO (dimethylsulfoxide). As the total nucleated cell (TNC)
dose is considered one of the most important factors for successful
engraftment, a re-exploration of the need to wash thawed UCB cells
has been underway in many centers. To control for all UCB unit
variables (cryo bags, volumes etc.) and standardize thawing process
we established a methodology and made it our standard operating
procedure (SOP) after proper validation. Rather than washing,
our protocol uses a 4:1 dilution method that minimizes cell loss
and decreases DMSO concentrations to\ 2%. The diluent me-
dium consists of 8% human albumin in10% dextrose. Units are
thawed in a 37C water bath and then diluted over 12 minutes
with three rates set to deliver 10%, 30% and 60% of the volume
at 5%, 8% and 10% per minute respectively. After completion of di-
lution a sample is removed from the bag to perform viability, steril-
ity testing and TNC count and the cells are infused into the patients
over 15 minutes. Data was collected over 5 years (2002 to 2007) for
45 UCB transplants. All samples were negative for Sterility testing
and there were no adverse reaction during infusion. The recovery
and engraftment rates are as follows: Conclusion: The thaw dilu-
tion process without wash yielded a superior %TNC recovery
and %viability. All but one patient achieved ANC engraftment.
There were 7 (15%) early deaths due to infection. The ANC en-
graftment and 100 day survival was not significantly different be-
tween the 2 cell dose groups, but the platelet engraftment was
delayed in the group who received a TNC dose\1.5  107/kg.
We now target units with a cell dose of $ 1.5  107 TNC with
a minimum match of 4/6, but given the prompt ANC engraftment
seen, we continue to accept units of\1  107/kg processed in this
manner.
